ARCHIVES

ASCO Foundation Renamed

This article is from The Cancer Letter archive.

Vol. 37 No. 07 | February 18, 2011

Download PDF Visit The Full Archive

Related Articles

ACOS Survey To Assess Tumor Boards’ Impact On Patient Care

January 24, 1986

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

Weight Gain After Diagnosis Increases Risk Of Death

December 28, 2007

Gore, Agency Report, Support Legislation To Protect Genetic Info

January 30, 1998

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

March 29, 2013